{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:16:15Z","timestamp":1778800575034,"version":"3.51.4"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T00:00:00Z","timestamp":1352246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0044481","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T23:18:49Z","timestamp":1352330329000},"page":"e44481","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":55,"title":["The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy"],"prefix":"10.1371","volume":"7","author":[{"given":"Jennifer C.","family":"Irvine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virat","family":"Ganthavee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane E.","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy E.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes-Peter","family":"Stasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara K.","family":"Kemp-Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca H.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,11,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1056\/NEJM199910213411706","article-title":"Signaling pathways for cardiac hypertrophy and failure","volume":"341","author":"JJ Hunter","year":"1999","journal-title":"New Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1440-1681.2007.04585.x","article-title":"Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure","volume":"34","author":"JR McMullen","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref3","first-page":"649","article-title":"Emerging therapeutic targets in chronic heart failure: Part I. Exp Opin Therap Targets","volume":"6","author":"V Roenicke","year":"2002"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"JP Stasch","year":"2011","journal-title":"Circulation"},{"key":"ref5","first-page":"1039","article-title":"Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure","volume":"11","author":"J Tamargo","year":"2010","journal-title":"Curr Opin Invest Drugs"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00210-012-0730-6","article-title":"cGMP becomes a drug target","volume":"385","author":"J Schlossmann","year":"2012","journal-title":"Naunyn-Schmied Arch Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/cbf.290120303","article-title":"Guanylyl cyclases \u2013 a family of receptor-linked enzymes","volume":"12","author":"HJ Fulle","year":"1994","journal-title":"Cell Biochem Function"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pharmthera.2009.08.001","article-title":"Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO\u2022 and beyond","volume":"124","author":"RH Ritchie","year":"2009","journal-title":"Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"EJ Tsai","year":"2009","journal-title":"Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"H1370","DOI":"10.1152\/ajpheart.1998.275.4.H1370","article-title":"Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide","volume":"275","author":"RH Ritchie","year":"1998","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI119883","article-title":"Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts","volume":"101","author":"A Calderone","year":"1998","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/01.HYP.0000032854.74042.CF","article-title":"Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP","volume":"40","author":"AC Rosenkranz","year":"2002","journal-title":"Hypertension"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1006\/jmcc.2000.1149","article-title":"Endothelial dysfunction limits the antihypertrophic action of bradykinin in rat cardiomyocytes","volume":"32","author":"AC Rosenkranz","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Lin EQ, Irvine JC, Cao AH, Alexander AE, Love JE, <etal>et al<\/etal>.. (2012) Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation. Plos One 7: e34892, pages 1\u201310.","DOI":"10.1371\/journal.pone.0034892"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cardiores.2006.07.006","article-title":"Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes","volume":"72","author":"A Laskowski","year":"2006","journal-title":"Cardiovasc Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bjp.0706792","article-title":"NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5\/6 nephrectomy","volume":"148","author":"P Kalk","year":"2006","journal-title":"Br J Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.105.581405","article-title":"Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling","volume":"113","author":"R Dumitrascu","year":"2006","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2010.08.032","article-title":"BAY 41\u20132272 inhibits the development of chronic hypoxic pulmonary hypertension in rats","volume":"647","author":"LB Thorsen","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000092518","article-title":"BAY 41\u20132272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats","volume":"90","author":"P Deruelle","year":"2006","journal-title":"Biol Neonate"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.HYP.0000241087.12492.47","article-title":"Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats","volume":"48","author":"H Masuyama","year":"2006","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ygeno.2003.10.002","article-title":"Quantitative analysis of the cardiac fibroblast transcriptome-implications for NO\/cGMP signaling","volume":"83","author":"A Smolenski","year":"2004","journal-title":"Genomics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2174\/156652409789105499","article-title":"B-Type natriuretic peptide: endogenous regulator of myocardial structure, biomarker and therapeutic target","volume":"9","author":"RH Ritchie","year":"2009","journal-title":"Curr Mol Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"JP Stasch","year":"2001","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Stasch J-P, Hobbs AJ (2009) NO-Independent, haem-dependent soluble guanylate cyclase stimulators. In: Schmidt HHHW, Hofmann F, Stasch J-P, editors. cGMP: generators, effectors and therapeutic implications: Springer Berlin Heidelberg, p. 277\u2013308.","DOI":"10.1007\/978-3-540-68964-5_13"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","article-title":"NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle","volume":"136","author":"JP Stasch","year":"2002","journal-title":"Br J Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1172\/JCI28371","article-title":"Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels","volume":"116","author":"J-P Stasch","year":"2006","journal-title":"J Clin Invest"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1172\/JCI118462","article-title":"Regulation of calcium channel expression in neonatal myocytes by catecholamines","volume":"97","author":"T Maki","year":"1996","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/01.HYP.31.1.39","article-title":"Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells","volume":"31","author":"RH Ritchie","year":"1998","journal-title":"Hypertension"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0008-6363(02)00667-3","article-title":"Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP","volume":"57","author":"AC Rosenkranz","year":"2003","journal-title":"Cardiovasc Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.yjmcc.2007.03.900","article-title":"The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse <italic>in vivo<\/italic>","volume":"42","author":"RH Ritchie","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/ars.2007.9.101","article-title":"The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms","volume":"9","author":"SSC Goh","year":"2007","journal-title":"Antiox Redox Sig"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"H1179","DOI":"10.1152\/ajpheart.00725.2003","article-title":"Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling","volume":"287","author":"RH Ritchie","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(99)00559-2","article-title":"Effects of adrenomedullin on cultured rat cardiac myocytes and fibroblasts","volume":"382","author":"T Horio","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/01.RES.0000082524.34487.31","article-title":"Regulation of nitric oxide-sensitive guanylyl cyclase","volume":"93","author":"A Friebe","year":"2003","journal-title":"Circ Res"},{"key":"ref35","first-page":"L1124","article-title":"NADPH and heme redox modulate pulmonary artery relaxation and guanylate cyclase activation by NO. Am J Physiol Lung Cell Mol Physiol","volume":"277","author":"SA Gupte","year":"1999"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0014-2999(02)02453-6","article-title":"Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin","volume":"453","author":"T Nishikimi","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"H1697","DOI":"10.1152\/ajpheart.00595.2009","article-title":"Regulation of VASP phosphorylation in cardiac myocytes: differential regulation by cyclic nucleotides and modulation of protein expression in diabetic and hypertrophic heart","volume":"297","author":"JL Sartoretto","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/01.HYP.0000259328.04159.90","article-title":"Nitroxyl anion donor, Angeli&apos;s salt, does not develop tolerance in rat isolated aortae","volume":"49","author":"JC Irvine","year":"2007","journal-title":"Hypertension"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI27657","article-title":"Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system","volume":"116","author":"E Mergia","year":"2006","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.bjp.0707687","article-title":"Probing the presence of the ligand-binding haem in cellular nitric oxide receptors","volume":"153","author":"B Roy","year":"2008","journal-title":"Br J Pharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"L318","DOI":"10.1152\/ajplung.00062.2009","article-title":"Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus","volume":"297","author":"M Chester","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1476-5381.2009.00263.x","article-title":"Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation","volume":"157","author":"LS Hoffmann","year":"2009","journal-title":"Br J Pharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4161\/isl.2.6.13917","article-title":"Expression and functional roles of guanylate cyclase isoforms in BRIN-BD11 beta-cells","volume":"2","author":"MA Russell","year":"2010","journal-title":"Islets"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1476-5381.2010.00943.x","article-title":"The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide","volume":"161","author":"S Roger","year":"2010","journal-title":"Br J Pharmacol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/jpet.107.124594","article-title":"Effects of 5-Cyclopropyl-2-1-(2-fluoro-benzyl)-1H-pyrazolo 3,4-b pyridine-3-yl pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity\/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice","volume":"322","author":"CE Teixeira","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2010.07.028","article-title":"Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle","volume":"645","author":"HA Toque","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0735-1097(01)01826-5","article-title":"The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model","volume":"39","author":"M-O Date","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.vph.2010.09.008","article-title":"Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase","volume":"53","author":"S Roger","year":"2010","journal-title":"Vasc Pharmacol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/eurheartj\/ehp143","article-title":"BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts","volume":"30","author":"T Krieg","year":"2009","journal-title":"Eur Heart J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/jmcc.2002.1526","article-title":"Role of oxidative stress in myocardial hypertrophy and failure","volume":"34","author":"DB Sawyer","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4161\/cc.2.3.381","article-title":"Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival","volume":"2","author":"T Matsui","year":"2003","journal-title":"Cell Cycle"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.pharmtox.45.120403.095802","article-title":"The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure","volume":"45","author":"RD Brown","year":"2005","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1152\/ajprenal.00197.2005","article-title":"Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition","volume":"290","author":"Y Wang","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, <etal>et al<\/etal>.. (2011) Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. Plos One 6: e21853, pages 1\u201310.","DOI":"10.1371\/journal.pone.0021853"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.fjc.0000210071.54828.9b","article-title":"Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats","volume":"47","author":"M Zanfolin","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/hr.2009.64","article-title":"Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart","volume":"32","author":"H Masuyama","year":"2009","journal-title":"Hypertens Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0044481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T17:03:39Z","timestamp":1687799019000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0044481"}},"subtitle":[],"editor":[{"given":"Harald HHW.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,7]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0044481","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,7]]}}}